David Z I Cherney Selected Research

Sodium-Glucose Transporter 2 Inhibitors

7/2022	Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations.
4/2022	Potential Use of SGLT-2 Inhibitors in Obstructive Sleep Apnea: A new treatment on the horizon.
1/2022	Cardiorenal protection with SGLT2 inhibitors in patients with diabetes mellitus: from biomarkers to clinical outcomes in heart failure and diabetic kidney disease.
1/2022	SGLT2 Inhibition in Type 1 Diabetes with Diabetic Kidney Disease: Potential Cardiorenal Benefits Can Outweigh Preventable Risk of Diabetic Ketoacidosis.
1/2022	Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus.
1/2022	The differential effects of ertugliflozin on glucosuria and natriuresis biomarkers: Prespecified analyses from VERTIS CV.
10/2021	Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial.
8/2021	Markers of Kidney Injury, Inflammation, and Fibrosis Associated With Ertugliflozin in Patients With CKD and Diabetes.
8/2021	Kidney outcomes using a sustained ≥40% decline in eGFR: A meta-analysis of SGLT2 inhibitor trials.
5/2021	Renal haemodynamic and protective effects of renoactive drugs in type 2 diabetes: Interaction with SGLT2 inhibitors.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David Z I Cherney Research Topics

Disease

53	Type 2 Diabetes Mellitus (MODY) 04/2022 - 01/2015
50	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2022 - 10/2005
28	Chronic Renal Insufficiency 07/2022 - 01/2018
25	Diabetic Nephropathies (Diabetic Nephropathy) 07/2022 - 10/2014
23	Hyperglycemia 01/2019 - 10/2005
21	Heart Failure 07/2022 - 11/2014
14	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 01/2016
13	Albuminuria 07/2022 - 01/2017
12	Kidney Diseases (Kidney Disease) 01/2022 - 08/2013
6	Inflammation (Inflammations) 01/2022 - 12/2013
5	Hypertension (High Blood Pressure) 07/2022 - 01/2016
5	Body Weight (Weight, Body) 01/2022 - 03/2016
5	Chronic Kidney Failure (Chronic Renal Failure) 01/2022 - 06/2006
5	Proteinuria 01/2021 - 03/2016
4	Diabetes Mellitus 07/2022 - 01/2015
4	Myocardial Infarction 01/2022 - 09/2016
4	Stroke (Strokes) 01/2022 - 09/2016
4	Renal Insufficiency (Renal Failure) 10/2021 - 10/2020
4	Infections 01/2021 - 09/2016
3	Hypoglycemia (Reactive Hypoglycemia) 10/2021 - 05/2014
3	Acute Kidney Injury (Acute Renal Failure) 01/2021 - 09/2016
2	Diabetic Ketoacidosis (Ketoacidosis, Diabetic) 01/2022 - 01/2021
2	Atherosclerosis 11/2021 - 01/2019
2	Hypovolemia 10/2021 - 11/2019
2	Fibrosis (Cirrhosis) 08/2021 - 05/2016
2	Disease Progression 10/2020 - 01/2018
2	Glycosuria 03/2016 - 01/2015
1	Glomerulonephritis 07/2022
1	Obstructive Sleep Apnea 04/2022
1	Polyneuropathies (Polyneuropathy) 01/2022
1	Hyperkalemia 11/2021
1	Gout 10/2021
1	Diarrhea 01/2021
1	Renal Cell Carcinoma (Grawitz Tumor) 01/2021

Drug/Important Bio-Agent (IBA)

30	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 09/2010
29	Sodium-Glucose Transporter 2 InhibitorsIBA 07/2022 - 09/2016
25	Sodium-Glucose Transport ProteinsIBA 04/2022 - 02/2014
23	SodiumIBA 01/2022 - 10/2014
16	empagliflozinIBA 11/2021 - 02/2014
12	ertugliflozinIBA 01/2022 - 01/2020
11	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2009
10	CreatinineIBA 10/2021 - 01/2017
8	AlbuminsIBA 01/2021 - 01/2017
8	Inulin FDA Link 06/2019 - 02/2010
7	Uric Acid (Urate)IBA 01/2022 - 08/2013
7	dapagliflozinIBA 01/2022 - 01/2018
6	DiureticsIBA 01/2021 - 11/2017
6	CytokinesIBA 03/2016 - 01/2011
5	finerenoneIBA 12/2021 - 01/2018
5	ChemokinesIBA 03/2016 - 01/2011
4	ReninIBA 01/2021 - 02/2010
4	Insulin (Novolin)FDA Link 01/2021 - 05/2014
4	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2016 - 11/2008
3	Mineralocorticoid Receptor AntagonistsIBA 07/2022 - 01/2018
3	omega-Chloroacetophenone (Mace)IBA 01/2022 - 01/2018
3	DiamondIBA 01/2022 - 01/2020
3	AtrasentanIBA 01/2021 - 01/2018
3	Natriuretic AgentsIBA 01/2019 - 01/2017
3	Guanosine Monophosphate (5' Guanylic Acid)IBA 01/2019 - 05/2013
3	Angiotensin IIIBA 12/2018 - 07/2010
3	Hypoglycemic Agents (Hypoglycemics)IBA 11/2018 - 01/2017
3	CanagliflozinIBA 01/2018 - 01/2017
3	Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)IBA 11/2017 - 01/2017
3	aliskiren FDA Link 10/2013 - 02/2010
3	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 06/2010 - 03/2008
2	Glucagon-Like Peptide-1 Receptor AgonistsIBA 07/2022 - 06/2018
2	Hemoglobins (Hemoglobin)IBA 04/2022 - 09/2016
2	(2S,3R,4R,5S,6R)- 2- (4- chloro- 3- (4- ethoxybenzyl)phenyl)- 6- (methylthio)tetrahydro- 2H- pyran- 3,4,5- triolIBA 12/2021 - 01/2021
2	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 01/2021 - 01/2016
2	SymportersIBA 01/2021 - 10/2020
2	Proteins (Proteins, Gene)FDA Link 01/2020 - 08/2014
2	Cystatin CIBA 06/2019 - 01/2012
2	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2019 - 11/2012
2	Dipeptidyl-Peptidase IV InhibitorsIBA 06/2018 - 01/2017
2	IncretinsIBA 06/2018 - 05/2016
2	AngiotensinogenIBA 02/2017 - 08/2014
2	C-Reactive ProteinIBA 01/2016 - 11/2014
2	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 11/2014 - 01/2011
2	Chemokine CCL22IBA 11/2014 - 01/2011
2	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 10/2014 - 10/2005
2	Protein Kinases (Protein Kinase)IBA 01/2012 - 01/2009
2	ruboxistaurinIBA 01/2012 - 01/2009
2	Enalapril FDA LinkGeneric 01/2012 - 10/2005
2	Celecoxib (Celebrex)FDA Link 06/2010 - 03/2008
1	Endothelin Receptor AntagonistsIBA 07/2022
1	KetonesIBA 01/2022
1	Neurotransmitter Agents (Neurotransmitter)IBA 01/2022
1	Biological ProductsIBA 01/2022
1	Serum AlbuminIBA 01/2022
1	Glucagon-Like Peptide-1 ReceptorIBA 11/2021
1	LipidsIBA 11/2021
1	Allopurinol (Remid)FDA LinkGeneric 10/2021
1	Pharmaceutical PreparationsIBA 01/2021
1	ElectrolytesIBA 01/2021

Therapy/Procedure

20	Therapeutics 07/2022 - 06/2006
5	Glycemic Control 07/2022 - 05/2014
2	Kidney Transplantation 01/2022 - 10/2014
2	Secondary Prevention 12/2020 - 01/2016
2	Heart-Assist Devices 01/2016 - 11/2014
1	Renal Replacement Therapy (Therapies, Renal Replacement) 08/2021